Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau(Centre National de la Recherche Scientifique), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Lixia Pei(Nanjing University of Chinese Medicine), Laura Rosiñol(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Surbhi Sidana(Palo Alto University), Jesús F. San Miguel(Clinica Universidad de Navarra), Ajay K. Nooka(Emory University), Danielle Trancucci(Centre Hospitalier Universitaire de Nantes), Lionel Karlin(Hôpital Lyon Sud), María‐Victoria Mateos(Hospital Clínico San Carlos), Niels W.C.J. van de Donk(Oncode Institute), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Alfred L. Garfall(University of Pennsylvania), Shun Xin Wang Lin(Centre Hospitalier Universitaire de Nantes), Rian Van Rampelbergh(Janssen (Belgium)), Rachel Kobos(Centre Hospitalier Universitaire de Nantes), Hareth Nahi(Karolinska University Hospital), Albert Oriol(Institut Català d'Oncologia), Britta Besemer(Centre Hospitalier Universitaire de Nantes), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Thomas G. Martin(University of California San Francisco Medical Center), Nizar J. Bahlis(Institute of Cancer Research), Suzette Girgis(Centre Hospitalier Universitaire de Nantes), Lotfi Benboubker, Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Clarissa Uhlar(University of Pennsylvania), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Mindy Jaffe(Centre Hospitalier Universitaire de Nantes), Jenna D. Goldberg(Centre Hospitalier Universitaire de Nantes), Michel Delforge(KU Leuven), Ajai Chari(University of California, San Francisco), Amrita Krishnan(City of Hope), Yunsi Olyslager(Janssen (Belgium))
New England Journal of Medicine
June 5, 2022
Cited by 1,173


Related Papers